Although the experiments performed by Zhou et al.
United Therapeutics, GeNO, SoniVie, Arena, and Karos. 3) It is surprising that heart rate was unchanged after PADN. I would have expected the heart rate to slow after PADN, both because of reduced sympathetic activity and an increased stroke volume resulting from the reduction in right ventricular afterload. The reason for this, which may be consequential for PAH patients, is unclear.
Despite these limitations, the report by Zhou et al.
(4) not only provides support for a key role of the sympathetic nervous system in the pathogenesis of PAH but also suggests that an intervention designed to interrupt this sympathetic activation may be a novel and targeted approach to treatment of this condition. Although such an approach would be a welcomed addition to the therapeutic armamentarium for PAH, cautious evaluation in well-designed clinical trials will be necessary before the utility of PADN for PAH can be determined.
